Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
Safety and Tolerability of Au-TMP Nanoparticles in Combination With Radiotherapy for Patients With Advanced Melanoma Receiving Anti-PD-1 Therapy
調査の概要
詳細な説明
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Xingchen Peng, Professor
- 電話番号:+8618980606753
- メール:pxx2014@163.com
研究連絡先のバックアップ
- 名前:Yuting Yan, Doctor
- メール:yutingyan98@yeah.net
研究場所
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 募集
- West China Hospital, Sichuan University
-
コンタクト:
- Xingchen Peng, Ph.D
- 電話番号:+8618980606753
- メール:pxx2014@163.com
-
Chengdu、Sichuan、中国、610041
- まだ募集していません
- West China Hospital, Sichuan University
-
コンタクト:
- Xingchen Peng
- 電話番号:+8618980606753
- メール:pxx2014@163.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age: Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically confirmed unresectable Stage III or Stage IV melanoma without prior systemic therapy. Prior adjuvant or neoadjuvant therapy is permitted, provided it was completed at least 3 weeks before enrollment and all related adverse events (AEs) have resolved to baseline or NCI CTCAE v5.0 Grade ≤ 1.
- Presence of at least one measurable lesion according to RECIST v1.1 criteria.
- At least one lesion suitable for intratumoral injection and radiotherapy (located in the skin, subcutaneous tissue, superficial lymph nodes, or visceral lesions assessed as safe for access) that has not received prior radiotherapy (unless documented progression has occurred).
Adequate hematologic and organ function within 7 days prior to the first dose, including:
Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L; Platelet count (PLT) ≥ 90 × 10⁹/L; Hemoglobin (Hb) ≥ 90 g/L. (No Granulocyte-Colony Stimulating Factor (G-CSF), platelet transfusion, or Erythropoietin (EPO)/Red Blood Cell (RBC) transfusion within 14 days prior to testing).
Renal Function: Serum creatinine (Cr) ≤ 1.5 × Upper Limit of Normal (ULN), or calculated creatinine clearance (Ccr) ≥ 50 mL/min using the Cockcroft-Gault formula.
Hepatic Function: Total bilirubin (TBIL) ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with Gilbert's Syndrome or liver metastases); Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Alkaline Phosphatase (ALP) ≤ 2.5 × ULN (≤ 5.0 × ULN for patients with documented liver or bone metastases); Serum albumin ≥ 2.8 g/dL.
Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN.
Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50%.
- Anticipated survival time ≥ 16 weeks.
- Agreement to use highly effective contraception methods during the trial and for 12 months after the last dose of treatment.
- Voluntarily participate in the study, sign the Informed Consent Form (ICF), demonstrate good compliance, and be willing to cooperate with follow-up.
Exclusion Criteria:
- Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.
- Known hypersensitivity to recombinant humanized anti-PD-1 monoclonal antibodies or any of their components.
- Active skin breakdown, infection, ulceration, necrosis, bleeding at the injection site, or a high risk of hollow organ perforation.
- Known allergy or intolerance to Au-TMP active ingredients, excipients, or similar compounds.
- Presence of known driver mutations (e.g., BRAF V600E/K, c-KIT, NRAS) for which targeted therapies are already approved and available as first-line treatment.
- Ocular (uveal) or mucosal melanoma.
- Receipt of other anti-tumor therapies (including corticosteroids or immunotherapy) or participation in other clinical trials within 4 weeks before treatment initiation; failure to recover from toxicities of prior therapies (except Grade 2 alopecia and Grade 1 neurotoxicity).
- Pregnant or breastfeeding women.
- Positive for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV). Patients with positive Hepatitis B Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) must have a negative Hepatitis B Virus (HBV) DNA test (quantitative detection < 500 IU/mL).
- History of active tuberculosis.
- Active autoimmune disease requiring systemic treatment within the past 2 years (except physiological replacement therapy for thyroid, insulin, or adrenal/pituitary insufficiency).
- Serious uncontrolled concurrent medical conditions, including uncontrolled diabetes, interstitial lung disease, New York Heart Association (NYHA) Class III/IV heart failure, severe cardiac arrhythmias, or recent (within 6 months) myocardial infarction or cerebrovascular accidents.
- Active Central Nervous System (CNS) or leptomeningeal metastases. Patients with treated brain metastases are eligible if they are stable (no progression via Magnetic Resonance Imaging (MRI)) for at least 8 weeks post-treatment and 28 days prior to the first dose, and do not require immunosuppressive doses of corticosteroids (>10 mg/day prednisone equivalent) for at least 2 weeks.
- Receipt of hematopoietic stimulants (e.g., G-CSF, EPO) within 2 weeks prior to treatment.
- Receipt of live vaccines within 4 weeks prior to treatment.
- Major surgery (excluding diagnostic procedures) within 4 weeks prior to treatment.
- History of psychiatric disorders or persistent drug/substance abuse.
- Other malignancies within the past 5 years, except for successfully treated localized cancers such as basal/squamous cell skin cancer or in situ carcinomas (cervix, breast, prostate).
- Any other acute or chronic medical/psychiatric condition or laboratory abnormality that, in the investigator's opinion, increases research-related risk or interferes with the interpretation of study results.
- Any condition that is not in the best interest of the participant.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Au-TMP Plus Radiotherapy and Toripalimab
Patients receive a single intratumoral injection of Au-TMP followed by radiotherapy and systemic Toripalimab.
|
A single intratumoral injection of Au-TMP (at concentrations of 50 mg/mL using escalating dose levels of 5% or 10% of tumor volume)
Administration of Toripalimab (anti-PD-1 antibody) at a fixed dose of 240 mg, administered every 2 weeks (Q2W).
Local radiotherapy (RT) delivered to the injected tumor lesion, with a total dose of 30 Gy delivered in 5 fractions (6 Gy per fraction).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
時間枠:From the administration of Au-TMP (Day 1) through Day 28.
|
DLT is defined as any toxicity event occurring within the DLT observation period (from the day of Au-TMP intratumoral injection to Day 28) that is judged by the investigator to be related (possibly, probably, or definitely related) to Au-TMP and meets the pre-specified DLT criteria defined in the protocol.
|
From the administration of Au-TMP (Day 1) through Day 28.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetic (PK) Parameters
時間枠:Day 1 (pre-injection, 1h, 2h, 4h, 8h, 24h post-injection), and Days 4, 8, 15, 28.
|
Concentration-time curves and related PK parameters of gold (Au) elements in whole blood, plasma, and urine following intratumoral injection of Au-TMP.
|
Day 1 (pre-injection, 1h, 2h, 4h, 8h, 24h post-injection), and Days 4, 8, 15, 28.
|
|
Incidence and Severity of Adverse Events (AEs)
時間枠:Up to 12 months from the date of Au-TMP administration.
|
Incidence, severity, and causality of Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 Treatment-Related Adverse Events (TRAEs), and Serious Adverse Events (SAEs).
All events are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.
|
Up to 12 months from the date of Au-TMP administration.
|
|
Objective Response Rate (ORR)
時間枠:Baseline up to disease progression or up to 12 months from the date of Au-TMP administration
|
The proportion of participants who achieve a Complete Response (CR) or Partial Response (PR), assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria [with immune-modified RECIST (iRECIST) criteria as a secondary reference].
|
Baseline up to disease progression or up to 12 months from the date of Au-TMP administration
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) and Overall Survival (OS)
時間枠:From the date of Au-TMP administration until the date of first documented progression or death from any cause (up to 2 years)
|
PFS is defined as the time from Au-TMP administration to the first documented disease progression (PD) according to RECIST v1.1, or death due to any cause, whichever occurs first.
OS is defined as the time from Au-TMP administration to death from any cause.
For participants who are still alive at the end of the study, data will be censored at the last known date of follow-up.
|
From the date of Au-TMP administration until the date of first documented progression or death from any cause (up to 2 years)
|
|
Peripheral blood immune microenvironment changes
時間枠:Up to 3 months from the date of Au-TMP administration
|
Treatment-related dynamic changes in peripheral blood immune microenvironment, including: Frequency, absolute count, phenotype (activation/exhaustion markers), and functional status of key immune cell subsets (e.g., Cluster of Differentiation 8-positive (CD8+) T cells); Levels of relevant cytokines (e.g., Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)). |
Up to 3 months from the date of Au-TMP administration
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011 Feb 25;11:85. doi: 10.1186/1471-2407-11-85.
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
- Bonvalot S, Rutkowski PL, Thariat J, Carrere S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baere T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Verges R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovee JVMG, Le Pechoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8.
- Zhang Y, Huang F, Ren C, Liu J, Yang L, Chen S, Chang J, Yang C, Wang W, Zhang C, Liu Q, Liang XJ, Liu J. Enhanced Radiosensitization by Gold Nanoparticles with Acid-Triggered Aggregation in Cancer Radiotherapy. Adv Sci (Weinh). 2019 Jan 8;6(8):1801806. doi: 10.1002/advs.201801806. eCollection 2019 Apr 17.
- Jiang Y, Cao H, Deng H, Guan L, Langthasa J, Colburg DRC, Melemenidis S, Cotton RM, Aleman J, Wang XJ, Graves EE, Kalbasi A, Pu K, Rao J, Le QT. Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors. Nat Biotechnol. 2025 Sep;43(9):1496-1509. doi: 10.1038/s41587-024-02448-0. Epub 2024 Oct 24.
- Gorodetska I, Schulz A, Behre G, Dubrovska A. Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies. Cancers (Basel). 2025 Aug 14;17(16):2648. doi: 10.3390/cancers17162648.
- Zhao Y, Zhang T, Wang Y, Lu D, Du J, Feng X, Zhou H, Liu N, Zhu H, Qin S, Liu C, Gao X, Yang Z, Liu Z. ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proc Natl Acad Sci U S A. 2021 Apr 6;118(14):e2010333118. doi: 10.1073/pnas.2010333118.
- Sheng X, Huang G, Fang M, Li K, Wu D, Zhang X, Chen J, Zhu D, Chen Y, Li H, Gao Q, Wu L, Tang B, Yan X, Zeng R, Li J, Yu W, Xu J, Hao Y, Jin C, Zou J, Guo J. Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial. JAMA Oncol. 2026 Mar 1;12(3):243-250. doi: 10.1001/jamaoncol.2025.5751.
- Jalil A, Donate MM, Mattei J. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. Cancer Drug Resist. 2024 Oct 31;7:42. doi: 10.20517/cdr.2024.54. eCollection 2024.
- Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14.
- Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version). Chin J Cancer Res. 2019 Aug;31(4):578-585. doi: 10.21147/j.issn.1000-9604.2019.04.02. No abstract available.
- Okobi OE, Abreo E, Sams NP, Chukwuebuni OH, Tweneboa Amoako LA, Wiredu B, Uboh EE, Ekechi VC, Okafor AA. Trends in Melanoma Incidence, Prevalence, Stage at Diagnosis, and Survival: An Analysis of the United States Cancer Statistics (USCS) Database. Cureus. 2024 Oct 2;16(10):e70697. doi: 10.7759/cureus.70697. eCollection 2024 Oct.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-811
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。